Sitemap
Pages
- Leadership (July 16, 2020)
- Bioanalytical Science (July 17, 2020)
- Biomarker Science (July 28, 2020)
- Research and Development (July 29, 2020)
- Pharmacokinetics (August 4, 2020)
- New Header (September 23, 2020)
- Operations (June 7, 2021)
- Home (June 11, 2021)
- Therapeutic Expertise (June 14, 2021)
- Careers (August 25, 2021)
- News (November 2, 2021)
- PBMC Isolation (November 11, 2021)
- Webinars (December 1, 2021)
- Privacy (February 11, 2022)
- Cookie-policy (February 11, 2022)
- Terms of use (February 11, 2022)
- Executive Board (May 11, 2022)
- Non-Executive Team (May 11, 2022)
- Contact Sales (May 27, 2022)
- Submit RFI/RFP (May 30, 2022)
- Career Enquiries (May 30, 2022)
- General Enquiries (June 6, 2022)
- Sitemap (September 9, 2022)
- Events (February 17, 2023)
- Thank you (June 8, 2023)
- Impressum (June 9, 2023)
- About (October 19, 2023)
- Solutions for Clinical Research (October 20, 2023)
- Translational (October 24, 2023)
- Synexa Team (October 25, 2023)
- Biomarker- Solutions (October 25, 2023)
- Bioanalysis (October 26, 2023)
- Biomarker Consulting (October 26, 2023)
- Tissue Imaging & Cell Solutions (October 26, 2023)
- Flow Cytometry (October 26, 2023)
- Why Synexa (October 30, 2023)
- Vaccines (October 30, 2023)
- Autoimmune (October 30, 2023)
- Biosimilars (October 30, 2023)
- Immuno Oncology (October 30, 2023)
- Kimberg Internship (November 1, 2023)
- Opportunities (November 1, 2023)
- Why Join Synexa (November 6, 2023)
- Contact (November 6, 2023)
- Proteomics (February 2, 2024)
- Genomics (April 23, 2024)
- Radiopharmaceutical Bioanalysis (May 9, 2024)
- cmxm (September 26, 2024)
- ELISpot (November 6, 2024)
- Environmental Sustainability (February 4, 2025)
- Mass Spectrometry (April 29, 2025)
- Immunoassay (April 29, 2025)
Blog Articles
- A unifying expression signature for SLE (July 16, 2020)
- Complement C4 Genes and Sex-Biased Disease Susceptibility (July 16, 2020)
- Potential concussion biomarkers discovered in circulating blood after brain injury (July 16, 2020)
- Immune checkpoint inhibitors and MDSCs (July 16, 2020)
- Faecal Calprotectin as a biomarker in Crohn’s disease (July 24, 2020)
- Immune biomarkers in depression (July 24, 2020)
- Rapid expansion of Treg cells protects from collateral colitis following a viral trigger (September 18, 2020)
- The prospect of immunotherapy for combating Alzheimer’s disease (September 18, 2020)
- Macrophages transfer mitochondria to sensory neurons to resolve inflammatory pain (September 18, 2020)
- Spot on: Use of Dried Blood Spots (DBS) for serological immunoassays (September 18, 2020)
- Th17 Cells and IL-17: a possible link between inflammation and neuronal decline in Multiple Sclerosis (September 18, 2020)
- Infertility and the importance of the endometrial immune balance (February 15, 2021)
- The Biomarker Association between Depression and Vascular Disease (February 15, 2021)
- Synexa raises awareness for Rare Diseases Day (February 28, 2022)
- Lipids as Biomarkers of Brain Disorders (March 24, 2022)
- Fibrosis and SMAD signalling (April 22, 2022)
- A Quick Guide to Biomarker Solutions (August 3, 2022)
- Where Does Bioanalysis Fit into Drug Discovery Pipelines? (August 19, 2022)
- What are Immune Checkpoint Inhibitors? (August 26, 2022)
- How to Accelerate Pre-Clinical Trials with Flow Cytometry (September 21, 2022)
- How to Measure Bacteriophages in Clinical Studies for Antimicrobial Agents (September 30, 2022)
- Enhancing PCR Molecular Diagnostics Using Immunoassays (October 7, 2022)
- A Brief Introduction To Novel Modalities (November 2, 2022)
- Using Exosomes As Clinical Biomarkers (November 18, 2022)
- How Immunogenomics Factors into Cell and Gene Studies (November 29, 2022)
- What Biomarkers Are Used For CNS Drug Development? (February 9, 2023)
- Understanding the Role of Phenotypic Assays in Drug Research (February 24, 2023)
- How Cytokine Release Assays Work in Predictive Immunotoxicology (March 10, 2023)
- The Current State of Tuberculosis Research | World TB Day (March 24, 2023)
- Parkinson’s Disease Biomarker Assessment: New Approaches and Directions (April 11, 2023)
- Improving the World’s First Malaria Vaccine (April 26, 2023)
- Monitoring Immune Response in Pediatric Vaccine Recipients (April 27, 2023)
- Asthma Care for All (May 2, 2023)
- Biomarkers for Dementia (May 17, 2023)
- Challenges and Opportunities: Development of the HIV vaccine (May 18, 2023)
- Liquid biopsies: a non-invasive picture of cancer physiology (July 12, 2023)
- Advances in Autoimmune Hepatitis Biomarkers: Improving Diagnosis and Treatment Outcomes (July 28, 2023)
- Revolutionizing Lung Cancer Treatment with CAR-T Cell Therapy (August 1, 2023)
- Biomarkers in saliva: A novel approach to endometriosis (August 17, 2023)
- The standardization of synuclein seed amplification assays (August 30, 2023)
- Uncovering tissue complexity through spatial biology (September 15, 2023)
- AI-assisted pathology for precision medicine: Are we there yet? (October 5, 2023)
- Bioanalytical Strategies for Cell Therapy Clinical Trials (December 6, 2023)
- Top 3 Biotech Trends in 2024 | Dr. Nicholas Woudberg (January 8, 2024)
- Top 3 Biotech Trends in 2024 | Dr. Caroline Beltran (January 9, 2024)
- The criticality of early detection of pre-eclampsia: New biomarkers (January 24, 2024)
- Mycobacterium leprae: The lazy cousin to Tuberculosis (January 29, 2024)
- World Cancer Day 2024: Closing the gap (February 5, 2024)
- Modelling Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): A rare autoimmune disease (February 29, 2024)
- Cardiovascular complications in chronic kidney disease: New biomarkers and treatment (March 13, 2024)
- Bridging the Gap: Translating Animal Model Findings to Clinical Oncology Breakthroughs (March 20, 2024)
- From Pottiphar to Potts: Skeletal TB from Ancient Egypt to the Present Day (April 5, 2024)
- Primary Immunodeficiency Week: A complex landscape of genetic disorders (April 23, 2024)
- Primary Immunodeficiency Week: The promise of gene therapy (April 25, 2024)
- World Preeclampsia Day 2024: A spotlight on the neurological consequences (May 17, 2024)
- World Multiple Sclerosis Day 2024: Wider access to crucial antibody therapies (May 30, 2024)
- Patient Derived Organoids: Shaping the Fight Against Paediatric Brain Cancer (June 7, 2024)
- Falling drug approval rates: What should we be doing differently? (August 6, 2024)
- The STING in the tail: How our own defense mechanisms to infection may be working against us (August 29, 2024)
- The mpox outbreak: Variants, transmission and the boost for vaccine manufacturers (September 5, 2024)
- A controlled detonation: Targeted antibody drug conjugates (ADCs) for oncology (September 17, 2024)
- Allogeneic CAR T cell therapies: A major step forward (October 9, 2024)
- Identifying biomarkers of success: Integrated bioanalysis for glioblastoma CAR-T cell clinical trials (October 18, 2024)
- The Next Frontier for CAR T-Cell Therapy: Shifting Gears to Autoimmune Conditions (February 18, 2025)
- Quantitative Analysis of Oligonucleotides: An out of the box LC-MS/MS approach (March 5, 2025)
- Building a bioanalytical workflow for a vaccine study: The key assays and considerations (March 12, 2025)
- Radiopharmaceutical Drug Development: A Bioanalytical Lab Perspective (May 8, 2025)
- Why The Future Of Precision Medicine Will Be Defined By The Quality And Strategy Of Biomarker Signatures (May 15, 2025)
- Establishing Biosimilarity: Regulatory and Scientific Expectations (June 5, 2025)
Feature Articles
- Lack of implantation of an embryo: when the numbers count (July 23, 2020)
- SARS CoV-2: when does the calm become the perfect storm? (July 24, 2020)
- NanoString nCounter Technology – COVID-19 Immunological and Inflammatory Response (October 2, 2020)
- Immunogenicity 101: Antidrug Antibodies, Neutralizing Antibodies, and everything in between (January 20, 2021)
- Behind the wave (May 20, 2021)
Brochures
- COVID-19: Biomarker Analysis (March 23, 2021)
- Bioanalytical Solutions for Immuno-oncology Therapeutics (August 10, 2022)
- Translational Solutions (August 10, 2022)
- Biomarker and Bioanalytical Solutions (August 10, 2022)
- Laboratory Solutions for Vaccine Clinical Trials (August 24, 2023)
- Bioanalytical Solutions for CAR-T and NK Cell Therapies (August 24, 2023)
- Complete Laboratory Solution for Vaccine Studies (November 9, 2023)
- Translational Services for Gastroenterology Research (January 19, 2024)
- Lupus Biomarker Discovery (January 26, 2024)
- Allogeneic Cell Therapy Services (January 26, 2024)
- Biomarker and Bioanalysis Solution for Pulmonary Disease (April 23, 2024)
- Flow Cytometry Services (June 21, 2024)
- TBNK Flow Cytometry Panel (June 21, 2024)
- Large Molecule Bioanalysis Services (June 21, 2024)
- Radiopharmaceutical Bioanalysis Solutions (June 24, 2024)
- LC/MS-MS Bioanalytical Solutions (June 11, 2025)
- Comprehensive Bioanalytical Solutions for Antibody-Drug Conjugates (ADCs) (June 12, 2025)
- ELISpot Assay Services (June 12, 2025)
webinars
- Accelerating TB Vaccine Development: Insights from Microsampling, Biomarkers and Data Analysis (May 18, 2023)
- Enhancing Flow Cytometry Precision and Accuracy in Immuno-Oncology Studies (August 28, 2023)
- Persistence is key: Bioanalytical Strategies for Cell Therapy Clinical Trials (April 9, 2024)
- The Human Touch; patient-derived data from Synexa Prototrials® (April 11, 2024)
- Key Insights for Biosimilar Method Development and Validation (May 7, 2024)
- Autoimmune Biomarker Profiling: Over a Decade of Experience in Lupus (August 12, 2024)
- Radiopharmaceutical Bioanalysis Solutions (September 27, 2024)
- Overcoming Challenges in ELISpot Method Development and Validation to Support Clinical Trials (April 9, 2025)
Datasheets
News
- Synexa Announces Tripartite Collaboration (March 23, 2021)
- Synexa Life Sciences Co-founder and CEO to become company’s Chairman (May 13, 2022)
- Synexa Life Sciences announces strategic growth plans and strengthening of its executive team (May 18, 2022)
- Synexa Life Sciences acquires Finnish CRO Syrinx Bioanalytics to expand bioanalysis capabilities (May 19, 2022)
- Synexa Life Sciences expands operations in North America with new Rockville laboratory site (June 13, 2022)
- Synexa Life Sciences to appoint Chief Commercial Officer to support company growth ambitions (August 19, 2022)
- Synexa Life Sciences celebrates its 20th anniversary (March 3, 2023)
- Synexa Life Sciences Joins CEPI in Advancing Global Epidemic Preparedness and Response (May 30, 2023)
- Synexa Life Sciences hosts German Parliamentary Sub-Committee on Global Health at Cape Town laboratories (February 9, 2024)
- Synexa Life Sciences Expands Biomarker Discovery Capabilities with the Addition of Olink® Target Platform (March 4, 2024)
- Announcing the 2024 Kimberg Internship Program: Nurturing the Next Generation of Scientific Leaders (June 5, 2024)
- Synexa Life Sciences Enrols in My Green Lab Certification Program (July 10, 2024)
- Synexa Life Sciences Expands Bioanalysis Capabilities with the Acquisition of CRO Alderley Analytical (October 7, 2024)
- Paul Holme joins the Synexa Global Management Team as Chief Operating Officer (January 24, 2025)
- Sally Hannam Strengthens Synexa’s Scientific Expertise as Scientific Director (January 30, 2025)
- Synexa Life Sciences Achieves Highest Level My Green Lab Certification, Reinforcing Commitment to Lab Sustainability (February 4, 2025)
- Claire Wildgoose Appointed General Manager of Synexa Life Sciences – UK (February 11, 2025)
- Synexa Life Sciences Partners with Waters to Trial Xevo TQ Absolute XR Mass Spectrometer (June 10, 2025)
- Synexa Life Sciences Achieves Gyrolab CRO Certification (June 11, 2025)
